Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07598708 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
A Phase 2 study, sponsored by Centessa Pharmaceuticals (UK) Limited.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 222
- Enrollment target
NCT07598708 is a Phase 2 study that is actively recruiting participants, run by Centessa Pharmaceuticals (UK) Limited. The registered enrollment target is 222 participants.
The verdict
NCT07598708, a Phase 2 study, is actively recruiting participants, sponsored by Centessa Pharmaceuticals (UK) Limited.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 222 participants
- Enrollment target
Study Summary
Narcolepsy Type 1 (NT1) and Narcolepsy Type 2 (NT2) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness \[EDS\]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities. While all conditions result in feeling sleepy, there are some differences in other common symptoms: * NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night. * NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy. Orexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable cleminorexton is in NT1 and NT2 and learn about what the drug does to the body. Another goal of the study is to see if cleminorexton can help people with NT1 and NT2 feel less sleepy and make other symptoms better.
Interventions
- DRUG Placebo
- DRUG cleminorexton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2026-05-29 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07598708
The ClinicalTrials.gov registry entry for NCT07598708 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centessa Pharmaceuticals (UK) Limited, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07598708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07598708 about?
NCT07598708 is a clinical study titled "A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence". Narcolepsy Type 1 (NT1) and Narcolepsy Type 2 (NT2) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness \[EDS\]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, workin...
What is the current status of trial NCT07598708?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 222 participants. The study started on 2026-05-29. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT07598708?
The interventions under investigation include: Placebo (DRUG), cleminorexton (DRUG).
Who is sponsoring clinical trial NCT07598708?
This trial is sponsored by Centessa Pharmaceuticals (UK) Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.